Last updated: March 6, 2026
What Is Acetrizoate Sodium?
Acetrizoate sodium is an iodinated radiocontrast agent used historically in imaging procedures. It is a water-soluble compound, primarily used for radiographic contrast enhancement in medical diagnostics before the decline of iodinated contrast agents due to safety concerns and the development of alternative imaging modalities.
Market Overview
Current Status in Market
- Market Presence: Acetrizoate sodium is largely obsolete in developed markets. Its decline results from safety issues such as nephrotoxicity and adverse allergic reactions linked to iodinated contrast agents.
- Manufacturing and Supply: Remaining manufacturing occurs mostly under legacy or niche supply chains, primarily for research or specific historical batch requirements.
- Regulatory Status: It is rarely approved for new use; most jurisdictions have revoked or suspended approvals due to safety concerns, limiting commercial viability.
Market Size and Trends
| Year |
Estimated Global Market (USD millioner) |
Change from Prior Year |
Comments |
| 2018 |
200 |
- |
Decline began around 2010 due to safety issues |
| 2020 |
150 |
-25% |
Usage restricted to research or legacy applications |
| 2022 |
100 |
-33% |
Market continues to shrink |
Source: Market research reports (e.g., Frost & Sullivan, 2021)
Competitive Landscape
- Key Compounds: Iohexol, iopamidol, iodixanol.
- Market Dynamics: The global iodinated contrast media market is valued at approximately USD 2 billion in 2022, with a CAGR of 4.5%. The shift favors newer agents with improved safety profiles.
Investment Fundamentals
R&D and Commercial Viability
- Patent Status: No recent patents, with patent expirations dating back over 25 years.
- Regulatory Pathways: Likely to face significant hurdles; gaining approval for new indications or reintroduction hinges on safety data and regulatory acceptance.
- Patentability: Limited opportunity, as chemical structures are well known; new formulations or delivery methods might generate patentability, but market size remains limited.
Production and Cost Considerations
- Manufacturing Complexity: Low; synthesis involves well-established iodination techniques.
- Cost of Production: Relatively low; raw materials are inexpensive, and production processes are mature.
- Supply Chain: Limited current demand reduces incentives for dedicated manufacturing lines.
Commercial and Strategic Factors
- Market Demand: Declining. Most hospitals and imaging centers transitioned to safer contrast agents.
- Regulatory Risks: High. Market re-entry faces major approval barriers.
- Safety Profile: Poor; nephrotoxicity and allergic reactions reduce clinical utility.
Investment Outlook
| Aspect |
Assessment |
| Market Potential |
Negligible; limited to niche or legacy use |
| Regulatory Environment |
Restrictive; high barriers to re-approval |
| Competitive Advantage |
None; superseded by newer, safer agents |
| Revenue Potential |
Minimal; unlikely to generate significant revenue |
| Investment Risks |
High; market decline, regulatory hurdles, safety issues |
Conclusions
Investment in acetrizoate sodium for commercial purposes is not advisable. Its market is contracting, and regulatory and safety challenges are insurmountable for large-scale commercial re-entry. Opportunities remain only in niche research applications or as a chemical reference standard, which do not support significant financial returns.
Key Takeaways
- Acetrizoate sodium is a legacy iodinated contrast agent with no active commercial market.
- New approvals are unlikely due to safety concerns and regulatory barriers.
- Production costs are low, but demand is minimal.
- The overall investment outlook is poor, with high risk and limited upside.
- Alternative contrast agents dominate, eroding any potential niche markets further.
FAQs
1. Can acetrizoate sodium be repositioned for new medical uses?
No. Its safety profile limits use in new medical applications; regulatory hurdles further prevent reintroduction.
2. Are there any ongoing research efforts involving acetrizoate sodium?
Rarely. Most research centers on legacy data or chemical properties, not clinical applications.
3. Could patenting new formulations revive its market?
Highly unlikely. The basic compound is well known; innovations would need to demonstrate significant safety or usability advantages.
4. What are the primary safety concerns associated with acetrizoate sodium?
Nephrotoxicity, allergic reactions, and toxicity related to iodinated compounds.
5. What trends dominate the contrast media market today?
Preference for safer, non-iodinated agents and advanced imaging methods like MRI and ultrasound.
References:
- Frost & Sullivan. (2021). Global contrast media market report.
- U.S. Food and Drug Administration. (2021). Digest of iodinated contrast media safety alerts.
- MarketWatch. (2022). Contrast agents market size and forecast.
- European Medicines Agency. (2019). Summary of safety concerns in iodinated contrast media.
